Comparison of drug survival between infliximab and adalimumab in inflammatory bowel disease

Background Conventional therapy of inflammatory bowel disease with traditional immunosuppressant medication is increasingly being replaced by biological agents. However, the response to these biological agents may be lost over time, with discontinuation being a marker of loss of effectiveness. There...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of clinical pharmacy 2020-04, Vol.42 (2), p.500-507
Hauptverfasser:	Gil-Candel, Mayte, Gascón-Cánovas, Juan José, Urbieta-Sanz, Elena, Rentero-Redondo, Lorena, Onteniente-Candela, María, Iniesta-Navalón, Carles
Format:	Artikel
Sprache:	eng
Schlagworte:	Adalimumab - blood Adalimumab - therapeutic use Adult Anti-Inflammatory Agents - blood Anti-Inflammatory Agents - therapeutic use Cohort Studies Colon Crohn's disease Drug Monitoring - trends Drug withdrawal Female Follow-Up Studies Gastrointestinal Agents - blood Gastrointestinal Agents - therapeutic use Humans Immunotherapy Inflammatory bowel disease Inflammatory bowel diseases Inflammatory Bowel Diseases - blood Inflammatory Bowel Diseases - drug therapy Inflammatory Bowel Diseases - epidemiology Infliximab Infliximab - blood Infliximab - therapeutic use Internal Medicine Intestine Male Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Patients Pharmacy Research Article Retrospective Studies Spain - epidemiology Statistical analysis Survival Therapeutic drug monitoring TNF inhibitors Treatment Outcome Tumor Necrosis Factor-alpha Tumor necrosis factor-TNF Tumor necrosis factor-α Tumors Ulcerative colitis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!